Moderna (NASDAQ:MRNA) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Moderna stock on October 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Moderna Trading Down 7.0%

Shares of NASDAQ MRNA traded down $17.34 on Thursday, hitting $231.35. The company had a trading volume of 6,963,200 shares, compared to its average volume of 16,037,005. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $280.80. The business has a 50 day moving average of $200.18 and a two-hundred day moving average of $95.52.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. During the same period in the previous year, the company posted ($0.51) EPS. Moderna’s revenue for the quarter was up 29.2% on a year-over-year basis. As a group, research analysts predict that Moderna, Inc. will post -5.34 EPS for the current fiscal year.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 40,294 shares of Moderna stock in a transaction on Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the transaction, the president directly owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This trade represents a 2.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the sale, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 197,251 shares of company stock worth $33,875,904 over the last quarter. 10.80% of the stock is currently owned by company insiders.

Top Moderna Stories

Investors following MRNA have been watching these stories:

• Neutral Sentiment: Moderna presented an oncology-led growth strategy, including work on its personalized cancer vaccine. That pipeline could become a meaningful source of future growth, but its commercial potential remains uncertain and will take time to establish. Article: Moderna’s Oncology Growth Plan
• Negative Sentiment: Investors focused on the cost of that strategy: Moderna expects about $4 billion in cash costs in 2027. The planned investment raises the stakes for its cancer programs and could prolong the path to profitability. Article: Moderna Analyst Day Spending
• Negative Sentiment: Despite the raised forecast, coverage noted that Moderna’s 2026 revenue outlook may still be below analyst expectations, fueling concern about a potential sales shortfall. That outlook, combined with elevated investment needs, appears to have outweighed the positive updates. Article: Why Moderna Stock Dropped

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Dogwood Wealth Management LLC raised its stake in shares of Moderna by 158.8% during the third quarter. Dogwood Wealth Management LLC now owns 132 shares of the company’s stock valued at $25,000 after purchasing an additional 81 shares in the last quarter. Western Pacific Wealth Management LP bought a new stake in shares of Moderna during the 3rd quarter worth about $29,000. Allied Private Wealth LLC acquired a new stake in shares of Moderna in the 2nd quarter worth approximately $30,000. CENTRAL TRUST Co lifted its stake in shares of Moderna by 36.5% in the 3rd quarter. CENTRAL TRUST Co now owns 172 shares of the company’s stock worth $33,000 after acquiring an additional 46 shares during the period. Finally, Next Level Wealth Planning LLC bought a new position in shares of Moderna in the third quarter valued at approximately $34,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on MRNA shares. The Goldman Sachs Group upped their target price on shares of Moderna from $137.00 to $195.00 and gave the company a “neutral” rating in a research note on Monday. Citigroup reaffirmed a “sell” rating on shares of Moderna in a research note on Friday, October 23rd. William Blair cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 27th. Barclays upped their price objective on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. Finally, CLSA upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. Six research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $113.75.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.